Liver
Liver stiffness may predict transplant-free survival in PSC

  • August 31

Colon
Upadacitinib linked to higher remission after UC therapy failure

  • August 28

Colon
Smartphone hypnotherapy misses noninferiority threshold in IBS trial

  • August 28

Pancreas
FDA approves first RAS-targeted therapy for metastatic pancreatic cancer

  • August 26

Colon

FDA expands Stelara approval to pediatric ulcerative colitis

  • August 31

The label expansion makes ustekinumab the first approved therapeutic monoclonal antibody that does not target tumor necrosis factor-alpha for both main forms of pediatric inflammatory bowel disease, according to the FDA.

BROWSE BY TOPICS

The New Gastroenterologist

Substance use disorders in gastroenterology and hepatology: A practical guide for the general gastroenterologist

  • August 3

  • by Isabelle S. Byers, MD, Michelle Russin, MD, Sasha Deutsch-Link, MD, MSCR

GI and liver complications often bring these patients in first, and the authors say gastroenterologists are well placed to screen and treat.

Esophagus
Bridging the rural divide: Building a motility center in a critical access hospital

  • August 3

  • by Amber Charoen, MD, W. Michael McDonnell, MD, AGAF

“If large urban centers can run comprehensive motility labs, why can't a critical access hospital?”

Is professional coaching worth it? A practical guide for early-career gastroenterologists

  • August 3

  • by Mariam Naveed, MD, FACG, Kathryn E. Hutchins, MD, FACG

Two program directors on why coaching belongs at the start of a GI career, not after something has already gone wrong.

The Latest

August 31
Liver
Liver stiffness may predict transplant-free survival in PSC

  • by Julie Greenbaum

Five-year survival without transplant ranged from 94% among patients below 10 kPa to 46% among those at 15 kPa or higher.

August 31
Colon
FDA expands Stelara approval to pediatric ulcerative colitis

  • by Bob Alaburda

The label expansion makes ustekinumab the first approved therapeutic monoclonal antibody that does not target tumor necrosis factor-alpha for both main forms of pediatric inflammatory bowel disease, according to the FDA.

August 28
Colon
Upadacitinib linked to higher remission after UC therapy failure

  • by Doug Brunk

Real-world data show higher observed clinical, biochemical, and endoscopic remission rates with upadacitinib than with two other advanced therapies, although some longer-term secondary findings were exploratory.

August 28
Colon
Smartphone hypnotherapy misses noninferiority threshold in IBS trial

  • by Meg Barbor

In a 230-patient randomized trial, abdominal pain response was 48.1% with in-person hypnotherapy and 33.3% with smartphone-based treatment, although digital therapy may help expand access to gut-directed treatment.

August 27
Colon
Lynch syndrome surveillance linked to lower mortality, but not fewer cancers

  • by Doug Brunk

“More frequent colonoscopy may be less important than ensuring the colonoscopy is of high quality.”